mAbDx moves into new laboratory space in the Innovation Center at the University of Oregon Riverfront Research Park.
read moremAbDx Granted Approval for Development of Monoclonal Antibodies
mAbDx granted IACUC approval for the development of monoclonal antibodies and immunoassays to identify and study mitochondrial DAMPs. Project title: “Defining the contribution of mitochondrial damage-associated-molecular patterns (mtDAMPs) to the systemic inflammatory response syndrome (SIRS) after tissue injury”.
read moremAbDx and PeaceHealth Laboratories Sign Agreement for Sepsis Study
mAbDx and Peace Health Laboratories sign agreement for a collaborative clinical study to evaluate utility of sepsis biomarkers monitored with non-invasive sampling.
read morePeaceHealth Institutional Review Board (IRB) Approves mAbDx Clinical Study of Sepsis
PeaceHealth Institutional Review Board (IRB) approves a mAbDx clinical study to evaluate utility of sepsis biomarkers monitored with non-invasive sampling.
read moreEUROMIT 8 Research Report by CSO Michael Marusich: Non-invasive cheek swab sampling reveals mitochondrial dysfunction associated with HIV/AIDS antiretroviral therapy
Research presentation by mAbDx CSO Michael Marusich at EUROMIT 8, The Eighth European Meeting on Mitochondrial Pathology “From mitochondrial diseases to mitochondria in health and disease”, Zaragoza, Spain. Title: “OXPHOS Levels in Cheek Swabs Reveal Mitochondrial Dysfunction Associated with HIV/AIDS and/or Antiretroviral Therapy (ART).”
read more